Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 and Oxaliplatin Induction in Resectable Esophageal/GEJ Adenocarcinoma
NCT04097028Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Roswell Park Comprehensive Cancer Center. Started Dec 2019; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04097028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097028.